Stocks-1801.HK-Innovent Biologics Inc

1801.HK Innovent Biologics Inc

0 0 (0%)
Trade
Trade

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2022: Innovent Biologics Inc's revenues increased by 3.18% and amounted to 5.30B. Net income decreased by 193.75% to -2.53B. Net assets decreased by NaN to 12.40B and EPS decreased from N/A to -1.70.
1801.HK's Investor Relations
Income StatementBalance SheetCash Flow Statement
Gross Margin
80.79%
Net Profit Margin
-75.48%
Operating Margin
-37.80%
Return On Investment
-19.96%